Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

SomePoorGuy Jul. 14 at 10:52 PM

$CHRS Its my birthday on August 16th. We should know by then if my $400,000 lotto ticket is a winner or not. Lol

5 · Reply

Grandgustav Jul. 14 at 9:19 PM

$CHRS bought some Aug. 21 call options, my first ever. Fingers crossed

0 · Reply

Grandgustav Jul. 14 at 4:30 PM

$CHRS

2 · Reply

BigDaddyCapital Jul. 14 at 2:06 PM

$CHRS bios crashing and betting on Denny the shitco… hope it just tanks

1 · Reply

Samishere Jul. 14 at 1:45 PM

$CHRS What complete nonsense! Short interest keeps rising and SP keeps falling ! The pump spins are getting more creative, I’ll give you that!

2 · Reply

wall_e_street Jul. 14 at 11:34 AM

$CHRS To give you an idea of how wild that number is: a normal, stable stock (like Apple or Microsoft) usually has an implied volatility between 15% and 30%. The fact that Coherus ($CHRS) sits at 363% means the market maker is warning that the stock is about to make a gigantic leap. Funds are charging a premium for contracts because they know that the day Denny Lanfear releases the data, the stock won't just move 2% or 3%.

1 · Reply

wall_e_street Jul. 14 at 11:27 AM

$CHRS Put/Call Ratio of 0.16: According to Fintel records, for every 16 Put options (bearish bets) opened, there are 100 Call options (bullish bets) backing the movement. This highly aggressive imbalance in favor of Calls reflects that institutional money has high confidence in the medical results.Extreme Implied Volatility (IV): The indicator stands above 363%, according to OptionCharts. This means that market makers and funds are charging extremely high premiums because they know the stock will experience a massive move (a violent gap) upward or downward on the day of the announcement.🤞🤞🤞

0 · Reply

John1066 Jul. 14 at 9:22 AM

$CHRS given under securities law companies are not allowed to mislead investors we have to assume data is still imminent otherwise they would have to issue PR advising delayed. Still likely to be on ec day i’d say.

1 · Reply

Grandgustav Jul. 14 at 6:02 AM

$CHRS

1 · Reply

SomePoorGuy Jul. 13 at 7:42 PM

$CHRS I muted 2 people and all if a sudden barely anythinh is posted. Just like the volume today, gone.

2 · Reply

Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study

Jun 23, 2026, 2:00 PM EDT - 21 days ago

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Jun 4, 2026, 9:55 AM EDT - 5 weeks ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Coherus Oncology Proxy statement: Proxy filing

May 27, 2026, 4:30 PM EDT - 6 weeks ago

Coherus Oncology Transcript: AGM 2026

2026-05-11T23:20:35.000Z - 2 months ago

Coherus Oncology reports Q1 EPS (28c), consensus (26c)

May 11, 2026, 5:00 PM EDT - 2 months ago

Coherus Oncology Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

Coherus Oncology Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

Coherus Oncology Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T12:37:08.000Z - 2 months ago

Guggenheim starts Coherus with Buy on anti-tumor potential

2026-05-11T10:36:08.000Z - 2 months ago

Coherus Oncology initiated with a Buy at Guggenheim

May 5, 2026, 8:00 AM EDT - 2 months ago

Coherus Oncology Proxy statement: Proxy filing

May 4, 2026, 9:30 AM EDT - 2 months ago

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 3 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Coherus Oncology Proxy statement: Proxy filing

Mar 10, 2026, 2:50 PM EDT - 4 months ago

Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026

2026-03-09T20:40:57.000Z - 4 months ago

Coherus Oncology reports Q4 EPS (34c), consensus (31c)

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Coherus Oncology Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Coherus Oncology Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 4 months ago

Coherus Oncology Earnings release: Q4 2025

Mar 9, 2026, 4:15 PM EDT - 4 months ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 4, 2026, 11:50 AM EST - 4 months ago

Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:30 AM EST - 4 months ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 5 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 5 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

2026-02-13T11:50:56.000Z - 5 months ago

Coherus Oncology 28.6M share Spot Secondary priced at $1.75

Feb 12, 2026, 9:18 PM EST - 5 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

2026-02-12T21:12:06.000Z - 5 months ago

Coherus Oncology announces common stock offering, no amount given

2026-01-22T21:16:58.000Z - 6 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

2026-01-22T21:11:03.000Z - 6 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer

Jan 13, 2026, 1:30 PM EST - 6 months ago

Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 6 months ago

Coherus Oncology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:30 AM EST - 6 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:51:47.000Z - 6 months ago

Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug

Jan 5, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 17, 2025, 1:30 PM EST - 7 months ago

Coherus Oncology Transcript: Biotech Discovery Series

2025-12-08T13:45:59.000Z - 7 months ago

Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial

Dec 8, 2025, 8:30 AM EST - 7 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 18, 2025, 5:30 AM EST - 8 months ago

Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025

2025-11-13T22:35:29.000Z - 8 months ago

Coherus Oncology files $150M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 8 months ago

Coherus Oncology Registration statement: Registration Filing

Nov 10, 2025, 1:15 PM EST - 8 months ago

Coherus Oncology Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 8 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:14 PM EST - 8 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 8 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 9:05 AM EDT - 10 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 1:00 PM EDT - 10 months ago

Coherus Oncology Transcript: UBS Virtual Oncology Day

Sep 10, 2025, 11:00 AM EDT - 10 months ago

Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:25 PM EDT - 11 months ago

Coherus Oncology Transcript: Baird Global Healthcare Conference 2025

2025-09-04T11:35:24.000Z - 11 months ago

Coherus Biosciences upgraded to Buy from Neutral at Roth Capital

2025-09-04T11:35:13.000Z - 11 months ago

Coherus Biosciences upgraded to Buy from Hold at Maxim

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:41 PM EDT - 1 year ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 1 year ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Coherus Oncology Slides: Corporate Presentation

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2025

2025-05-30T12:11:11.000Z - 1 year ago

Coherus Biosciences completes transformation to Coherus Oncology

May 27, 2025, 3:00 PM EDT - 1 year ago

Coherus Oncology Transcript: 6th Annual Oncology Innovation Summit

2025-05-27T12:40:21.000Z - 1 year ago

Coherus Biosciences announces clinical collaboration with STORM Therapeutics

May 20, 2025, 12:00 PM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q1 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 9:00 AM EDT - 1 year ago

Coherus Oncology Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Transcript: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Press release: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Slides: KOL Event

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Annual report: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q4 2024

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 11:50 AM EST - 1 year ago

Coherus Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Transcript: at 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Slides: FY 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 3:15 PM EST - 1 year ago

Coherus Oncology Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Coherus Oncology Transcript: Status Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings release: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q2 2024

Aug 1, 2024, 9:00 AM EDT - 2 years ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 2 years ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Coherus Oncology Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 12:00 PM EDT - 2 years ago

Coherus Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Annual report: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 5, 2024, 8:00 AM EST - 2 years ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Jan 22, 2024, 8:30 AM EST - 2 years ago

Coherus Oncology Transcript: Investor Update

Jan 22, 2024, 8:30 AM EST - 2 years ago

Coherus Oncology Press release: Investor Update

Jan 22, 2024, 1:15 AM EST - 2 years ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 18, 2024, 4:05 PM EST - 2 years ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

SomePoorGuy Jul. 14 at 10:52 PM

$CHRS Its my birthday on August 16th. We should know by then if my $400,000 lotto ticket is a winner or not. Lol

5 · Reply

Grandgustav Jul. 14 at 9:19 PM

$CHRS bought some Aug. 21 call options, my first ever. Fingers crossed

0 · Reply

Grandgustav Jul. 14 at 4:30 PM

$CHRS

2 · Reply

BigDaddyCapital Jul. 14 at 2:06 PM

$CHRS bios crashing and betting on Denny the shitco… hope it just tanks

1 · Reply

Samishere Jul. 14 at 1:45 PM

$CHRS What complete nonsense! Short interest keeps rising and SP keeps falling ! The pump spins are getting more creative, I’ll give you that!

2 · Reply

wall_e_street Jul. 14 at 11:34 AM

1 · Reply

wall_e_street Jul. 14 at 11:27 AM

0 · Reply

John1066 Jul. 14 at 9:22 AM

1 · Reply

Grandgustav Jul. 14 at 6:02 AM

$CHRS

1 · Reply

SomePoorGuy Jul. 13 at 7:42 PM

$CHRS I muted 2 people and all if a sudden barely anythinh is posted. Just like the volume today, gone.

2 · Reply

Samishere Jul. 13 at 5:48 PM

$CHRS Ha, look bags ,, you’re only down 14% from last weeks great 2nd half data dump 🤣🤪🤣🤪🤣 😱

1 · Reply

Jack_Nicholson_Truth Jul. 13 at 5:11 PM

$CHRS Sami aka Chad Lawton aka bigdaddy aka John are ruining stocktwits and reddit on purpose. It's one paid Troll here who posts everyday since $0.70, yelling some new made up conspiracy. Data is coming soon, good or bad. Three trials within the next 2-3 weeks.

0 · Reply

WebRub Jul. 13 at 5:10 PM

$CHRS

1 · Reply

Samishere Jul. 13 at 4:16 PM

$CHRS I see psycho Jack_Ass pumper is losing his 💩 even more now. Hey bags, who are you going to believe? Bi Polar Pumptards or the millions & millions of short shares , shorted by highly trained professionals? Hey Jackass,,,,,,,

0 · Reply

Grandgustav Jul. 13 at 3:05 PM

$CHRS

1 · Reply

BigDaddyCapital Jul. 13 at 1:36 PM

$CHRS LOOK OUT BELOW!! DENNY THE DUMMY

0 · Reply

Samishere Jul. 13 at 1:25 PM

$CHRS The market hates Big Fat Liars! And Denny is the biggest & fattest liar in the Biotech Biz!

0 · Reply

Jack_Nicholson_Truth Jul. 13 at 1:23 PM

$CHRS it's official.. All of these accounts from Chad Lawton to Sami are the same person. Ai has detected same posts, overwhelming replies to the same scammers, same pattern!

0 · Reply

Samishere Jul. 13 at 12:53 PM

$CHRS Pumper arrogance starting to crack I see! No problem, go short! You’ll make a dollar a share by end of summer after Denny’s lie is exposed- again !

0 · Reply

Jack_Nicholson_Truth Jul. 13 at 12:35 PM

$CHRS here is paid Troll that posts as all these fake posts with other accounts. Here Sami aka bigdaddy aka John aka cps1973. Three posts in a year to post about sami aka bigdaddy. Paid fake bot activity!

1 · Reply

Jack_Nicholson_Truth Jul. 13 at 12:31 PM

$CHRS no news today likely means no news for the week. Makes sense since Friday opex has no oi. July 20–August 3, or approximately 4–14 trading days, assuming nothing is released today. July 20 is now the next plausible Monday. IGNORE THE SCAMMERS HERE WHO POST EVERYDAY WITH THEIR 100 FAKE ACCOUNTS.

1 · Reply

SHVR89 Jul. 13 at 3:44 AM

$CHRS

0 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26